Complete financial analysis of Galapagos NV (GLPGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galapagos NV, a leading company in the Biotechnology industry within the Healthcare sector.
- Dallah Healthcare Company (4004.SR) Income Statement Analysis – Financial Results
- Anhui Expressway Company Limited (0995.HK) Income Statement Analysis – Financial Results
- Andon Health Co., Ltd. (002432.SZ) Income Statement Analysis – Financial Results
- Videocon Industries Limited (VIDEOIND.NS) Income Statement Analysis – Financial Results
- WPP plc (WPP.L) Income Statement Analysis – Financial Results
Galapagos NV (GLPGF)
About Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 239.72M | 505.28M | 484.85M | 478.05M | 844.99M | 288.84M | 127.09M | 129.52M | 39.56M | 69.37M | 137.70M | 136.27M | 95.89M | 122.41M | 93.09M | 76.98M | 65.94M | 35.15M | 11.24M | 7.78M |
| Cost of Revenue | 35.99M | 12.08M | 1.63M | 523.67M | 427.32M | 322.88M | 218.50M | 139.57M | 129.71M | 111.11M | 41.30M | 48.18M | 124.99M | 116.02M | 85.10M | 27.77M | 30.17M | 19.53M | 4.83M | 1.29M |
| Gross Profit | 203.74M | 493.20M | 483.22M | -45.61M | 417.67M | -34.04M | -91.42M | -10.06M | -90.15M | -41.74M | 96.40M | 88.09M | -29.10M | 6.39M | 7.99M | 49.21M | 35.77M | 15.62M | 6.41M | 6.49M |
| Gross Profit Ratio | 84.99% | 97.61% | 99.66% | -9.54% | 49.43% | -11.79% | -71.93% | -7.77% | -227.87% | -60.17% | 70.01% | 64.64% | -30.35% | 5.22% | 8.59% | 63.93% | 54.25% | 44.43% | 57.04% | 83.44% |
| Research & Development | 241.29M | 515.08M | 491.71M | 523.67M | 427.32M | 322.88M | 218.50M | 139.57M | 129.71M | 111.11M | 99.38M | 80.26M | 0.00 | 0.00 | 0.00 | 38.73M | 30.63M | 15.86M | 6.70M | 5.44M |
| General & Administrative | 92.48M | 185.50M | 97.26M | 95.70M | 63.68M | 25.50M | 17.76M | 15.16M | 19.13M | 8.09M | 19.35M | 18.27M | 23.12M | 21.48M | 16.93M | 21.07M | 19.44M | 11.96M | 5.74M | 4.52M |
| Selling & Marketing | 1.78M | 54.03M | 69.96M | 66.47M | 24.58M | 4.15M | 2.80M | 1.79M | 1.18M | 992.00K | 2.41M | 2.13M | 2.27M | 2.59M | 2.08M | 2.33M | 2.46M | 1.97M | 421.00K | 134.00K |
| SG&A | 94.25M | 239.53M | 167.22M | 162.17M | 88.26M | 29.64M | 20.56M | 16.95M | 20.31M | 9.08M | 21.76M | 20.40M | 25.39M | 24.07M | 19.01M | 23.40M | 21.90M | 13.94M | 6.16M | 4.65M |
| Other Expenses | -7.56M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 327.99M | 760.72M | 648.81M | 656.69M | 474.69M | 333.64M | 216.89M | 141.01M | 129.01M | 105.32M | 106.37M | 90.19M | 3.84M | 4.92M | 6.06M | 61.30M | 50.99M | 26.81M | 12.78M | 10.10M |
| Cost & Expenses | 327.99M | 772.80M | 650.44M | 656.69M | 474.69M | 333.64M | 216.89M | 141.01M | 129.01M | 105.32M | 147.67M | 138.37M | 128.82M | 120.94M | 91.16M | 89.07M | 81.15M | 46.34M | 17.61M | 11.39M |
| Interest Income | 79.61M | 18.11M | 2.87M | 10.03M | 14.31M | 5.22M | 3.05M | 1.61M | 1.25M | 1.16M | 1.19M | 1.02M | 859.00K | 1.11M | 738.00K | 1.86M | 1.08M | 370.00K | 368.00K | 202.00K |
| Interest Expense | 1.97M | 6.97M | 11.66M | 9.39M | 1.30M | 780.00K | 936.00K | 47.00K | 46.00K | 110.00K | 157.00K | 150.00K | 1.65M | 1.56M | 711.00K | 5.13M | 1.75M | 1.06M | 369.00K | 162.00K |
| Depreciation & Amortization | 43.64M | 29.90M | 21.30M | 16.99M | 10.81M | 5.08M | 4.29M | 4.18M | 3.40M | 4.65M | 8.15M | 9.01M | 12.10M | 11.64M | 6.96M | 7.37M | 8.35M | 4.73M | 1.32M | 1.00M |
| EBITDA | 51.04M | -194.09M | -138.00M | -178.63M | 374.24M | -35.07M | -86.16M | -8.16M | -118.41M | -30.44M | -7.83M | 4.01M | -21.49M | 13.78M | 9.35M | -1.89M | -12.41M | -6.71M | -4.97M | -2.40M |
| EBITDA Ratio | 21.29% | -38.41% | -28.46% | -34.60% | 46.17% | -12.14% | -65.24% | -4.40% | -140.05% | -42.27% | -1.33% | 6.25% | -20.84% | 11.62% | 10.34% | -3.72% | -8.77% | -17.32% | -41.69% | -30.90% |
| Operating Income | -88.26M | -276.52M | -165.60M | -178.63M | 370.29M | -44.81M | -89.80M | -11.49M | -89.44M | -36.62M | -11.02M | -6.61M | -32.94M | 1.03M | 1.66M | -15.22M | -21.84M | -11.81M | -6.65M | -3.61M |
| Operating Income Ratio | -36.82% | -54.73% | -34.15% | -37.37% | 43.82% | -15.51% | -70.66% | -8.87% | -226.08% | -52.80% | -8.00% | -4.85% | -34.35% | 0.84% | 1.78% | -19.77% | -33.12% | -33.59% | -59.16% | -46.39% |
| Total Other Income/Expenses | 93.89M | 60.21M | 46.19M | -131.14M | -220.22M | 15.60M | -25.71M | 65.74M | -30.18M | 1.42M | 780.00K | 1.46M | -792.00K | -443.00K | 26.00K | -7.37M | -666.00K | -687.00K | -1.00K | 40.00K |
| Income Before Tax | 5.63M | -215.15M | -123.00M | -309.78M | 150.06M | -29.21M | -115.51M | 54.25M | -119.63M | -35.20M | -11.19M | -5.15M | -33.73M | 588.00K | 1.69M | -18.48M | -22.51M | -12.49M | -6.65M | -3.57M |
| Income Before Tax Ratio | 2.35% | -42.58% | -25.37% | -64.80% | 17.76% | -10.11% | -90.89% | 41.88% | -302.37% | -50.75% | -8.13% | -3.78% | -35.17% | 0.48% | 1.81% | -24.00% | -34.13% | -35.54% | -59.17% | -45.88% |
| Income Tax Expense | 9.61M | 2.84M | 2.42M | 1.23M | 214.00K | 50.00K | 198.00K | 235.00K | -1.22M | 2.10M | -3.12M | 569.00K | -630.00K | -3.78M | -1.32M | -3.89M | -558.00K | -1.16M | -110.00K | 21.00K |
| Net Income | 211.70M | -217.99M | -103.23M | -305.44M | 149.85M | -29.26M | -115.70M | 54.01M | -118.41M | 33.21M | -8.08M | -5.72M | -33.10M | 4.37M | 3.01M | -14.58M | -21.95M | -11.34M | -6.54M | -3.59M |
| Net Income Ratio | 88.31% | -43.14% | -21.29% | -63.89% | 17.73% | -10.13% | -91.04% | 41.70% | -299.29% | 47.88% | -5.87% | -4.20% | -34.52% | 3.57% | 3.23% | -18.95% | -33.29% | -32.25% | -58.19% | -46.15% |
| EPS | 0.06 | -3.32 | -1.58 | -4.69 | 2.60 | -0.56 | -2.34 | 1.18 | -3.32 | 1.10 | -0.28 | -0.22 | -1.25 | 0.17 | 0.14 | -0.69 | -1.06 | -0.84 | -0.73 | -0.60 |
| EPS Diluted | 3.21 | -3.32 | -1.58 | -4.69 | 2.60 | -0.56 | -2.34 | 1.14 | -3.32 | 1.10 | -0.28 | -0.22 | -1.25 | 0.17 | 0.13 | -0.69 | -1.06 | -0.84 | -0.73 | -0.60 |
| Weighted Avg Shares Out | 3.50B | 65.70M | 65.50M | 65.08M | 57.61M | 52.11M | 49.48M | 45.70M | 35.70M | 30.11M | 28.79M | 26.55M | 26.40M | 24.28M | 21.66M | 21.19M | 20.68M | 13.54M | 8.94M | 5.94M |
| Weighted Avg Shares Out (Dil) | 65.88M | 65.70M | 65.50M | 65.08M | 57.61M | 52.11M | 49.48M | 45.70M | 35.70M | 30.11M | 28.79M | 26.55M | 26.40M | 24.28M | 21.66M | 21.19M | 20.68M | 13.54M | 8.94M | 5.94M |
Source: https://incomestatements.info
Category: Stock Reports